Faron Pharmaceuticals Oy Future Growth
Future criteria checks 2/6
Faron Pharmaceuticals Oy is forecast to grow earnings and revenue by 17.3% and 47.3% per annum respectively while EPS is expected to grow by 35.5% per annum.
Key information
17.3%
Earnings growth rate
35.5%
EPS growth rate
| Biotechs earnings growth | 43.1% |
| Revenue growth rate | 47.3% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 25 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 7 | -31 | -36 | -32 | 3 |
| 12/31/2025 | 37 | -17 | -10 | -16 | 4 |
| 12/31/2024 | N/A | -27 | -18 | -18 | 4 |
| 6/30/2024 | N/A | -32 | -20 | -20 | N/A |
| 3/31/2024 | N/A | -31 | -22 | -22 | N/A |
| 12/31/2023 | N/A | -31 | -24 | -24 | N/A |
| 9/30/2023 | N/A | -30 | -24 | -24 | N/A |
| 6/30/2023 | N/A | -29 | -24 | -24 | N/A |
| 3/31/2023 | N/A | -29 | -24 | -24 | N/A |
| 12/31/2022 | N/A | -29 | -23 | -23 | N/A |
| 9/30/2022 | N/A | -26 | -23 | -23 | N/A |
| 6/30/2022 | N/A | -24 | -23 | -22 | N/A |
| 3/31/2022 | N/A | -22 | -23 | -22 | N/A |
| 12/31/2021 | N/A | -21 | -23 | -22 | N/A |
| 9/30/2021 | N/A | -21 | -22 | -21 | N/A |
| 6/30/2021 | N/A | -20 | -21 | -20 | N/A |
| 3/31/2021 | N/A | -19 | -19 | -19 | N/A |
| 12/31/2020 | N/A | -17 | -18 | -17 | N/A |
| 9/30/2020 | N/A | -16 | -16 | -16 | N/A |
| 6/30/2020 | N/A | -14 | -14 | -14 | N/A |
| 3/31/2020 | N/A | -14 | -13 | -13 | N/A |
| 12/31/2019 | N/A | -13 | -12 | -12 | N/A |
| 9/30/2019 | 0 | -13 | -12 | -12 | N/A |
| 6/30/2019 | 0 | -12 | -13 | -13 | N/A |
| 3/31/2019 | 0 | -16 | -17 | -17 | N/A |
| 12/31/2018 | 0 | -20 | -21 | -21 | N/A |
| 9/30/2018 | 1 | -24 | -23 | -23 | N/A |
| 6/30/2018 | 1 | -28 | -25 | -25 | N/A |
| 3/31/2018 | 1 | -25 | N/A | -22 | N/A |
| 12/31/2017 | 1 | -21 | N/A | -18 | N/A |
| 9/30/2017 | 2 | -17 | N/A | -16 | N/A |
| 6/30/2017 | 2 | -14 | N/A | -14 | N/A |
| 3/31/2017 | 2 | -12 | N/A | -12 | N/A |
| 12/31/2016 | 2 | -10 | N/A | -9 | N/A |
| 9/30/2016 | 0 | -9 | N/A | -8 | N/A |
| 6/30/2016 | 0 | -7 | N/A | -7 | N/A |
| 3/31/2016 | 1 | -7 | N/A | -7 | N/A |
| 12/31/2015 | 1 | -6 | N/A | -7 | N/A |
| 9/30/2015 | 1 | -5 | N/A | -5 | N/A |
| 6/30/2015 | 1 | -3 | N/A | -3 | N/A |
| 3/31/2015 | 1 | -2 | N/A | -1 | N/A |
| 12/31/2014 | 1 | -1 | N/A | 0 | N/A |
| 12/31/2013 | 0 | -2 | N/A | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4FR is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 4FR is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 4FR is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 4FR's revenue (47.3% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: 4FR's revenue (47.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 4FR's Return on Equity is forecast to be high in 3 years time